Sigma Planning Corp Increases Holdings in Cue Biopharma, Inc. (NASDAQ:CUE)

Sigma Planning Corp boosted its position in Cue Biopharma, Inc. (NASDAQ:CUE) by 50.9% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 401,325 shares of the company’s stock after buying an additional 135,295 shares during the period. Sigma Planning Corp owned approximately 0.83% of Cue Biopharma worth $304,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Vanguard Group Inc. lifted its holdings in shares of Cue Biopharma by 7.1% in the 1st quarter. Vanguard Group Inc. now owns 2,283,362 shares of the company’s stock valued at $4,316,000 after buying an additional 150,457 shares during the period. Good Life Advisors LLC lifted its holdings in Cue Biopharma by 23.1% in the third quarter. Good Life Advisors LLC now owns 400,000 shares of the company’s stock valued at $303,000 after acquiring an additional 75,000 shares during the period. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new stake in Cue Biopharma in the 2nd quarter worth approximately $66,000. Institutional investors and hedge funds own 35.04% of the company’s stock.

Cue Biopharma Stock Down 17.0 %

CUE opened at $1.25 on Friday. The company has a market cap of $60.56 million, a PE ratio of -1.28 and a beta of 1.80. The company has a 50-day moving average price of $1.14 and a 200 day moving average price of $1.16. Cue Biopharma, Inc. has a twelve month low of $0.45 and a twelve month high of $3.25. The company has a quick ratio of 2.06, a current ratio of 2.06 and a debt-to-equity ratio of 0.11.

Cue Biopharma (NASDAQ:CUE) last posted its quarterly earnings results on Wednesday, August 14th. The company reported ($0.20) earnings per share for the quarter, topping the consensus estimate of ($0.29) by $0.09. The firm had revenue of $2.66 million for the quarter, compared to the consensus estimate of $1.12 million. Cue Biopharma had a negative net margin of 566.02% and a negative return on equity of 142.93%. During the same period last year, the firm posted ($0.29) earnings per share. Sell-side analysts expect that Cue Biopharma, Inc. will post -0.73 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities analysts have recently weighed in on the stock. Stifel Nicolaus cut their target price on shares of Cue Biopharma from $8.00 to $4.00 and set a “buy” rating for the company in a report on Tuesday, August 20th. Piper Sandler lowered their target price on shares of Cue Biopharma from $8.00 to $3.00 and set an “overweight” rating on the stock in a research note on Friday, July 26th. Finally, JMP Securities dropped their price objective on Cue Biopharma from $15.00 to $2.00 and set a “market outperform” rating on the stock in a report on Friday, July 26th. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has an average rating of “Buy” and a consensus target price of $5.00.

About Cue Biopharma

Cue Biopharma, Inc, a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells directly within the patient's body. Its lead drug product candidate is CUE-101 for the treatment of human papilloma virus (HPV16+)-driven recurrent/metastatic head and neck cancer.